Avalo Therapeutics (AVTX) Depreciation and Depletion (2014 - 2017)
Avalo Therapeutics posted quarterly Depreciation and Depletion of $4906.0 for Q4 2017, down 23.2% year-on-year from $6388.0 in Q4 2016, and down 8.49% on a QoQ basis from $5361.0 in Q3 2017.
Avalo Therapeutics (AVTX) has 4 years of Depreciation and Depletion data on file, last reported at $4906.0 in Q4 2017.
- For the quarter ending Q4 2017, Depreciation and Depletion fell 23.2% year-over-year to $4906.0; the trailing twelve-month figure through Dec 2017 stood at $21956.0 (down 18.25% YoY), and the FY2025 full-year result was $300000.0, up 50.0% from the prior year.
- Depreciation and Depletion for Q4 2017 stood at $4906.0, down from $5361.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $7881.0 in Q4 2014 and bottomed at $4906.0 in Q4 2017.
- The 4-year median for Depreciation and Depletion is $6148.0 (2015), against an average of $6169.3.
- The widest annual swing landed in 2016, when Depreciation and Depletion advanced 22.99%; it then declined 23.98% in 2017.
- A 4-year view of Depreciation and Depletion shows it stood at $7881.0 in 2014, then decreased by 21.99% to $6148.0 in 2015, then advanced by 3.9% to $6388.0 in 2016, then slipped by 23.2% to $4906.0 in 2017.
- The last three Depreciation and Depletion figures came in at $4906.0 (Q4 2017), $5361.0 (Q3 2017), and $5859.0 (Q2 2017), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 4,906.00 |
| Dec 31, 2017 | 4,906.00 |
| Sep 30, 2017 | 5,361.00 |
| Sep 30, 2017 | 5,361.00 |
| Jun 30, 2017 | 5,859.00 |
| Jun 30, 2017 | 5,859.00 |
| Mar 31, 2017 | 5,830.00 |
| Mar 31, 2017 | 5,830.00 |
| Dec 31, 2016 | 6,388.00 |
| Dec 31, 2016 | 6,388.00 |
| Sep 30, 2016 | 7,052.00 |
| Sep 30, 2016 | 7,052.00 |
| Jun 30, 2016 | 6,628.00 |
| Jun 30, 2016 | 6,628.00 |
| Mar 31, 2016 | 6,788.00 |
| Mar 31, 2016 | 6,788.00 |
| Dec 31, 2015 | 6,148.00 |
| Dec 31, 2015 | 6,148.00 |
| Sep 30, 2015 | 6,322.00 |
| Sep 30, 2015 | 6,322.00 |
| Jun 30, 2015 | 5,519.00 |
| Jun 30, 2015 | 5,519.00 |
| Mar 31, 2015 | 5,519.00 |
| Mar 31, 2015 | 5,519.00 |
| Dec 31, 2014 | 7,881.00 |
| Dec 31, 2014 | 7,881.00 |